Form D · Biotechnology
Anuncia Medical, Inc.
Scottsdale, AZ · CIK 0001889938
Offering snapshot reported Nov 21, 2025 · SEC filing
- Reported sold
- $13.9M Offering amount: $16.4M
- Investors reported
- 87 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Aug 30, 2024 As reported in this filing
Fundraising history
Reported soldDates are filing dates, not cash receipt dates. Decreases are reported revisions, not evidence of withdrawals. Separate offering histories are not added together.
What changed?
Latest filing versus its linked predecessor, where available.
- Reported sold$12,189,298 → $13,908,008
- Reported investors69 → 87
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Nov 21, 2025 | Amendment | $13,908,008 | $1,718,710vs Nov 18, 2024 | 87 | SEC filing |
| Nov 18, 2024 | Amendment | $12,189,298 | $1,437,437vs Sep 12, 2024 | 69 | SEC filing |
| Sep 12, 2024 | Initial | $10,751,861 | No comparison | 66 | SEC filing |
| Apr 24, 2024 | Amendment | $3,409,306 | $795,000vs Oct 19, 2023 | 28 | SEC filing |
| Oct 19, 2023 | Amendment | $2,614,306 | $788,699vs Mar 29, 2023 | 22 | SEC filing |
| Mar 29, 2023 | Amendment | $1,825,607 | $827,000vs Sep 8, 2022 | 14 | SEC filing |
| Sep 8, 2022 | Initial | $998,607 | No comparison | 8 | SEC filing |
| Dec 17, 2021 | Amendment | $427,500 | $300,000vs Oct 25, 2021 | 7 | SEC filing |
| Oct 25, 2021 | Initial | $127,500 | No comparison | 2 | SEC filing |
Offering details
- Securities
- Equity, Option to acquire, Security to be acquired
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $66.5K
- Form D file number
- 021-523914
Amounts include conversion of outstanding promissory notes. In addition, the Company has offered 5-year warrants to purchase up to a maximum of 886,839 shares at $0.2819 per share.
Sales compensation recipients
Scroll to see all columns →
| Recipient | CRD | Associated broker-dealer |
|---|---|---|
| U.S. Boston Capital Corporation | 5251 |
Source: Form D, filed Nov 21, 2025. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Elsa Abruzzo | Director, Executive |
| Pj Anand | Director |
| Darryl Baker | Executive |
| David Donabedian | Director |
| Edgar D Janotta | Director |
| Ghassan Kassab | Director |
| Stephen Oesterle | Director |
| Stanton Rowe | Director |
| Natalie Stevens | Executive |
| Richard Upton | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
6908 E Thomas Rd. Suite 302
Scottsdale, AZ, 85251
Scottsdale, AZ, 85251